Insider Buying: AstraZeneca PLC (LON:AZN) Insider Purchases 20,000 Shares of Stock

AstraZeneca PLC (LON:AZN) insider Pascal Soriot acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were acquired at an average price of £102.03 ($131.30) per share, with a total value of £2,040,600 ($2,625,916.87).

AstraZeneca Stock Down 2.9 %

Shares of LON:AZN opened at GBX 9,993.35 ($128.60) on Friday. The business has a fifty day simple moving average of £117.63 and a 200 day simple moving average of £121.45. AstraZeneca PLC has a 12-month low of GBX 9,461 ($121.75) and a 12-month high of £133.88 ($172.28). The firm has a market cap of £154.90 billion, a P/E ratio of 3,267.30, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. JPMorgan Chase & Co. reissued an “overweight” rating and set a £140 ($180.16) target price on shares of AstraZeneca in a research note on Thursday, November 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($141.55) price objective on shares of AstraZeneca in a research note on Tuesday, September 3rd. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Finally, Berenberg Bank reissued a “buy” rating and set a £150 ($193.03) price objective on shares of AstraZeneca in a report on Monday, September 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of £104.12 ($133.99).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.